Format

Send to

Choose Destination
Psychopharmacology (Berl). 2011 Feb;213(4):791-7. doi: 10.1007/s00213-010-2037-y. Epub 2010 Oct 8.

Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors.

Author information

1
Department of Neuroscience, University of Turin Medical School and National Institute of Neuroscience (INN), Turin, Italy. fabrizio.benedetti@unito.it

Abstract

RATIONALE:

Placebos are known to induce analgesia through the activation of μ-opioid receptors in some circumstances, such as after morphine pre-conditioning, an effect that is blocked by opioid antagonists.

OBJECTIVES:

On the basis of the anti-opioid action of cholecystokinin, here we tested whether the activation of the cholecystokinin type-2 receptors abolishes opioid-induced placebo responses.

METHODS:

The activation of the cholecystokinin type-2 receptors was performed by means of the agonist pentagastrin, and placebo responses were obtained after morphine pre-conditioning in an experimental human model of pain (tourniquet technique).

RESULTS:

Opioid-induced placebo responses were completely disrupted by pentagastrin administration. In addition, a high correlation between the response to morphine and the response to placebo was found, and this correlation was completely abolished by pentagastrin.

CONCLUSION:

These results show that the cholecystokinin-2 receptor agonist, pentagastrin, has the same effect as the μ-opioid receptor antagonist, naloxone, on placebo analgesia induced by morphine pre-conditioning, which suggests that the balance between cholecystokinergic and opioidergic systems is crucial in placebo responsiveness in pain. These findings also suggest that cholecystokinin type-2 receptor hyperactivity might be present in placebo non-responders.

PMID:
20931328
DOI:
10.1007/s00213-010-2037-y
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Springer Icon for University of Turin Instituional Repository AperTO
Loading ...
Support Center